# Skye Bioscience (SKYE) — News

SKYE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/skye/news

## Recent headlines

- [Arecor Therapeutics - Net proceeds to strengthen balance sheet, extend cash runway to December 2027](https://www.ainvest.com/news/arecor-therapeutics-net-proceeds-strengthen-balance-sheet-extend-cash-runway-december-2027-2609) — AInvest Wire, Sep 30, 2026
  Arecor Therapeutics has entered into a formulation development collaboration with Skye Bioscience to identify and develop higher concentration formulations of nimacimab , a key asset in Skye’s clinical pipeline. This partnership is part of Skye’s broader strategy to advance nimacimab through…
- [Skye Bioscience - John P. Sharp resigns as CFO and principal financial officer effective Sept 8, 2026 - SEC filing](https://www.ainvest.com/news/skye-bioscience-john-sharp-resigns-cfo-principal-financial-officer-effective-sept-8-2026-sec-filing-2609) — AInvest Wire, Sep 11, 2026
- [Skye Bioscience - enters $22 mln securities purchase agreement with Redmile Biopharma Investments III - SEC filing](https://www.ainvest.com/news/skye-bioscience-enters-22-mln-securities-purchase-agreement-redmile-biopharma-investments-iii-sec-filing-2608) — AInvest Wire, Aug 24, 2026
  Skye Bioscience, Inc. (Nasdaq: SKYE) has entered into a securities purchase agreement with Redmile Biopharma Investments III, a fund affiliated with Redmile, as part of a broader financing initiative tied to its pending merger with Redx Pharma. The agreement includes a committed equity line…
- [Skye Bioscience: quarterly EPS $-0.27 - SEC filing](https://www.ainvest.com/news/skye-bioscience-quarterly-eps-0-27-sec-filing-2608) — AInvest Wire, Aug 14, 2026
  Skye Bioscience Inc. reported a quarterly earnings per share (EPS) loss of $-0.27 for the most recent quarter, as disclosed in a recent SEC filing [1]. The negative EPS reflects the company’s ongoing financial challenges, which include significant research and development expenditures typical of…
- [Skye Bioscience - holders to receive CVR for 90% of Nimacimab net proceeds for 12 months post-closing](https://www.ainvest.com/news/skye-bioscience-holders-receive-cvr-90-nimacimab-net-proceeds-12-months-post-closing-2608) — AInvest Wire, Aug 14, 2026
  Skye Bioscience, Inc. (Nasdaq: SKYE) has announced that holders of its convertible debt will receive contingent value rights (CVRs) entitling them to 90% of the net proceeds from Nimacimab for a period of 12 months following the closing of a potential transaction. This arrangement is part of the…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).